Tisotumab Vedotin
Cervical Cancer
Seagen Inc.antibody_drug_conjugatePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 89/ 100
Competitive context
159 Active assets in the Cervical Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine Ditartrate UNICANCER | Phase 2 | BBB |
Carboplatin Merck Sharp & Dohme LLC | Phase 3 | B |
Cis-Diamminedichloroplatinum Ii Uganda Cancer Institute | Phase 3 | B |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | B |
Cyclophosphamide Merck Sharp & Dohme LLC | Phase 3 | B |
View all 50 →
Same molecule, other indications
Tisotumab Vedotin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →